Positive data from Oxxon hepatitis B trial
15th Nov 2005, 12:04 GMT
Interim data from Oxxon Therapeutics' phase IIa trial evaluating its PrimeBoost immunotherapeutic approach in patients with chronic hepatitis B has suggested safety and promising efficacy for the treatment.
Positive data from Oxxon hepatitis B trial related news:
- Positive phase I trial for Schering-Plough HCV treatment — Pharmaceutical Business Review Online
- XTLbio antibody reduces hepatitis C viral load in trial — Pharmaceutical Business Review Online
- SciClone Announces Data Presentations at AASLD Regarding ZADAXIN's Activity in Hepatitis B — Operations-Related News from StratCenter.com
- Positive early trial for Vertex drug — Pharmaceutical Business Review Online
- Hepatitis treatment studies' results announced — OnMedica Latest News
- HIV-positive man to face murder trial — thestar.com: News Top Stories
- Angiotech announces positive interim safety data with Vascular Wrap at one year — Pharmaceuticals News from StratCenter.com
- InterMune Releases Daily Infergen Data — Bio-Technology News from StratCenter.com
- HIV-positive man to stand trial on murder charges — CTV Canada
- SciClone Pharmaceuticals, Inc.: SciClone Announces Data Presentations at AASLD Regarding ZADAXIN's Activity in Hepatitis B — Market Wire - Pharmaceuticals and Biotech
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol